about
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerationsThromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review.Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia.Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.My patient is thrombocytopenic! Is (s)he? Why? And what shall I do? A practical approach to thrombocytopenia.Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency.von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems.Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura."HIT on Trousseau" double trouble: acquired coagulopathy with femoral artery thrombosis.Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment.Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA.Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients.A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenonThe new direct oral anticoagulants in special indications: rationale and preliminary data in cancer, mechanical heart valves, anti-phospholipid syndrome, and heparin-induced thrombocytopenia and beyond.Bilateral periorbital ecchymoses. An often missed sign of amyloid purpura.Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: Comparison of diagnostic accuracy, reproducibility, and costs in clinical practice.Prediction of Post-Weaning Fibrinogen Status during Cardiopulmonary Bypass: An Observational Study in 110 Patients.All platelets are not equal: COAT platelets.Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation studyCitrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytesDoes point of care prothrombin time measurement reduce the transfusion of fresh frozen plasma in patients undergoing major surgery? The POC-OP randomized-controlled trial.Chickenpox is not always benign: postvaricella purpura fulminans requires prompt and aggressive treatment.Do we need antiplatelet therapy in thrombocytosis? Pro. Diagnostic and pathophysiologic considerations for a treatment choice.Protein modelling to understand FGB mutations leading to congenital hypofibrinogenaemia.Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland.Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study.Thromboembolie und Antikoagulation bei Tumorpatienten.On the dosing of lepirudin.Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface.[Oral anticoagulation with vitamin K antagonists]Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study.Stability of low molecular weight heparin anti-factor Xa activity in citrated whole blood and plasma.Circadian variation of ticagrelor-induced platelet inhibition in healthy adulty.Vox Sanguinis International Forum on platelet cryopreservation: Summary.Vox Sanguinis International Forum on platelet cryopreservation.Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?
P50
Q28078404-C28A0E81-9935-4A79-8954-B50812CFDF62Q31112836-5D35909F-EB4D-40BA-9AA5-EDE49E23A9D9Q33343048-C53E6F86-AC85-4339-A11D-EC9292C4935AQ33346954-B0716AB2-7DFB-4FE8-B84D-78F21F109EAFQ33348070-31615B81-1055-4021-805B-91BA4339E3B0Q33349552-665FFC51-DB8A-4819-BB04-E533941C0F8EQ33355843-8EE51084-FBF3-42D2-8E19-829D1061C2E9Q33358599-DB149752-CBCB-4472-832F-63824206C869Q33358607-88135007-DCDF-4D0F-BDE3-8D479F73BA28Q33359530-9263F51C-AF58-45CD-94A9-B061A4D538DCQ33359981-EE523A8B-DB6B-4E3D-95FF-37EF9A74D3E8Q33380675-0CF12FF8-A936-4D8F-B354-2DCE72FB5E5DQ33380712-C1A64950-8CF1-4AD6-A61B-2E4BA18C0C03Q33382316-F0BF847B-69C7-402A-A747-920AEE2A0925Q33384943-79908CC2-7735-4E5C-85E6-59F9393B4816Q33397294-B041E41D-A5D8-485F-A217-B7BE26A1140FQ33415150-3BE5A01A-1CA1-4FB8-BF54-84C208184ACDQ33415514-8FEC4150-CEAE-4825-8638-A1E979601759Q33416165-AC29BC7C-11C7-42F6-8343-28713C95EDA3Q33442535-BFD3E491-88DE-4148-9637-0AE5FA9F8238Q35642006-E7069121-40B7-4766-AE57-BD9DAF472A29Q35876480-4CDB5448-8200-43AB-BED1-667CE03294C8Q36689644-13101BF8-EB44-40F8-83F0-FB7600735CC4Q37132012-17E8DCDC-EDBF-45DD-A79C-7A6A4E409511Q37448482-36F263D5-1688-43F8-8AD0-338B04661170Q37816169-584C2C7B-0FCC-46EB-80A8-01644646BD9AQ38364446-E1CD32F4-D347-4DDB-9EC5-B041A03FDDE3Q38901304-357CABDB-743F-410B-8B82-0E140CC8E364Q40018362-5A70535B-8026-4985-9E13-3A6F80DFD29EQ40185654-E35EA665-0CA5-407B-9924-715F6F5B830EQ40398463-95CF263F-4763-4EC9-BDCD-A5CAB1B20A8DQ42942412-7F604D43-EA81-48C6-BF30-E6CB53B2A63DQ43863360-38786977-8B0A-47EE-A69B-6B95DB326A8FQ44362903-90399DDE-9182-4CBC-8AB0-DC3988010A5AQ45057598-6647FFF1-9EC7-442A-A072-11180D07C59CQ47374737-7C9E78C9-1BBE-4DE6-8321-EF224E123F34Q47549080-3C28E782-8AED-429C-BFF5-AE9E76AE1042Q47565277-D267B3B5-3076-4278-A9DF-AB0087B5C0D9Q47565285-C70963D0-1552-4A6F-9972-D551BA9EC8D3Q47826895-A52CAEC6-6A53-4608-97C8-EEA3EC259DBF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lorenzo Alberio
@ast
Lorenzo Alberio
@en
Lorenzo Alberio
@es
Lorenzo Alberio
@nl
type
label
Lorenzo Alberio
@ast
Lorenzo Alberio
@en
Lorenzo Alberio
@es
Lorenzo Alberio
@nl
prefLabel
Lorenzo Alberio
@ast
Lorenzo Alberio
@en
Lorenzo Alberio
@es
Lorenzo Alberio
@nl
P106
P21
P31
P496
0000-0001-9686-9920